Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin.

Szczegóły
Abstrakt

Tytuł:: Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin.
Autorzy:: Yildirim N; Department of Medical Oncology, Firat University School of Medicine, Elazıg, Turkey. .
Cengiz M; Department of Internal Medicine, Biruni University School of Medicine, İstanbul, Turkey.
Źródło:: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Oct; Vol. 28 (10), pp. 4781-4788. Date of Electronic Publication: 2020 Jan 23.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Berlin : Springer International, c1993-
MeSH Terms:: Oxaliplatin/*adverse effects
Peripheral Nervous System Diseases/*chemically induced
Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Capecitabine/administration & dosage ; Capecitabine/adverse effects ; Colorectal Neoplasms/blood ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Incidence ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Logistic Models ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Oxaliplatin/administration & dosage ; Oxaloacetates/administration & dosage ; Oxaloacetates/adverse effects ; Peripheral Nervous System Diseases/blood ; Peripheral Nervous System Diseases/pathology ; Retrospective Studies ; Vitamin D/blood
References:: Kim DY, Kim JH, Lee S-H, Kim TY, Heo DS, Bang YJ, Kim NK (2003) Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 14(3):383–387. https://doi.org/10.1093/annonc/mdg106. (PMID: 10.1093/annonc/mdg10612598342)
Scagliotti GV, Kortsik C, Dark GG et al (2005) Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 11(2 Pt 1):690–696. (PMID: 15701857)
Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, Catalano V, Graziano F, Santini D, Tonini G (2013) Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer 21(5):1313–1319. https://doi.org/10.1007/s00520-012-1667-5. (PMID: 10.1007/s00520-012-1667-523196819)
André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351. https://doi.org/10.1056/ NEJMoa032709.
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapyinduced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020. (PMID: 10.1016/j.pain.2014.09.02025261162)
Briani C, Argyriou AA, Izquierdo C et al (2014) Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst 19(4):299–306. (PMID: 10.1111/jns.12097)
Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y (2013) Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer 21(12):3307–3313. (PMID: 10.1007/s00520-013-1905-5)
Comella P, Lorusso V, Maiorino L, Casaretti R, Cannone M, Massidda B, Putzu C, Leo S, Roselli M, Mancarella S, Palmeri S, Greco E, Vessia G, Sandomenico C, Franco L (2009) Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. Cancer Chemother Pharmacol 64(5):893–899. (PMID: 10.1007/s00280-009-0938-4)
Giacchetti S, Perpoint B, Zidani R, le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, le Rol A, Walter S, Adam R, Misset JL, Lévi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136–147. (PMID: 10.1200/JCO.2000.18.1.136)
Altaf R, Lund Brixen A, Kristensen B, Nielsen SE (2014) Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. Oncology 87(3):167–172. (PMID: 10.1159/000362668)
Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol 24(3):394–400. (PMID: 10.1200/JCO.2005.03.0106)
Velasco R, Bruna J, Briani C et al (2014) Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry 85(4):392–398. (PMID: 10.1136/jnnp-2013-305334)
Alejandro LM, Behrendt CE, Chen K, Openshaw H, Shibata S (2013) Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol 36(4):331–337. (PMID: 10.1097/COC.0b013e318246b50d)
Attal N, Bouhassira D, Gautron M, Vaillant JN, Mitry E, Lepère C, Rougier P, Guirimand F (2009) Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain 144(3):245–252. (PMID: 10.1016/j.pain.2009.03.024)
Won HH, Lee J, Park JO, Park YS, Lim HY, Kang WK, Kim JW, Lee SY, Park SH (2012) Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 118(11):2828–2836. (PMID: 10.1002/cncr.26614)
Shahriari-Ahmadi A, Fahimi A, Payandeh M, Sadeghi M (2015) Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran. Asian Pac J Cancer Prev 16(17):7603–7606. (PMID: 10.7314/APJCP.2015.16.17.7603)
Nagata T, Fukuda KI, Tamai M, Taniguchi A, Kamiya H, Kambe K, Kamada Y, Iwata G, Yamaoka N (2019) Early neuropathy related to oxaliplatin treatment in advanced and recurrent colorectal cancer. Anticancer Res 39(3):1347–1353. (PMID: 10.21873/anticanres.13248)
Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, Remick SC, Sharma S, Mani S, Ramanathan RK, Synold TW, Doroshow JH, Hamilton A, Mulkerin DL, Ivy P, Egorin MJ, Grem JL (2007) Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 13:4832–4839. (PMID: 10.1158/1078-0432.CCR-07-0475)
Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, Barg FK (2012) Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer 20(10):2433–2439. https://doi.org/10.1007/s00520-011-1365-8. (PMID: 10.1007/s00520-011-1365-822231480)
Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, Gollhofer A, Bloch W, Baumann FT (2014) Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 44(9):1289–1304. https://doi.org/10.1007/s40279-014-0207-5. (PMID: 10.1007/s40279-014-0207-524927670)
Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ (2001) Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 24(3):495–499. (PMID: 10.2337/diacare.24.3.495)
Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055–4061. (PMID: 10.1158/1078-0432.CCR-03-0666)
Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL (2011) Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29:421–427. (PMID: 10.1200/JCO.2010.31.5911)
Knijn N, Tol J, Koopman M, Werter MJ, Imholz AL, Valster FA, Mol L, Vincent AD, Teerenstra S, Punt CJ (2011) The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 47:369–374. (PMID: 10.1016/j.ejca.2010.10.006)
Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H (2010) Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 15:82–87. (PMID: 10.1007/s10147-009-0015-3)
Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/alliance). J Clin Oncol 32:997–1005. (PMID: 10.1200/JCO.2013.52.0536)
Aring AM, Jones DE, Falko JM (2005) Evaluation and prevention of diabetic neuropathy. Am Fam Physician 71:2123–2128. (PMID: 15952441)
Ramanathan RK, Rothenberg ML, de Gramont A (2010) Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol 21:754–758. (PMID: 10.1093/annonc/mdp509)
Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Heinze G, Rahhal-Schupp J, Reinthaller A, Concin N, Polterauer S (2013) Association of gamma-glutamyl transferase with severity of disease at diagnosis and prognosis of ovarian cancer. Br J Cancer 109(3):610–614. (PMID: 10.1038/bjc.2013.323)
Pandur S, Pankiv S, Johannessen M, Moens U, Huseby NE (2007) Gamma-glutamyl transferase is up regulated after oxidative stress through the Ras signal transduction pathway in rat colon carcinoma cells. Free Radic Res 41:1376–1384. (PMID: 10.1080/10715760701739488)
Corti A, Franzini M, Paolicchi A, Pompella A (2010) Gamma-glutamyl transferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res 30:1169–1181. (PMID: 20530424)
Wang J, Udd KA, Vidisheva A et al (2016) Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Support Care Cancer 24(7):3105–3110. https://doi.org/10.1007/s00520-016-3126-1. (PMID: 10.1007/s00520-016-3126-126902977)
Grim J, Ticha A, Hyspler R, Valis M, Zadak Z (2017) Selected risk nutritional factors for chemotherapy-induced polyneuropathy. Nutrients 9(6):535. (PMID: 10.3390/nu9060535)
Contributed Indexing:: Keywords: Gastrointestinal system cancers; Oxaliplatin; Peripheral neuropathy; Toxicity; Treatment
Substance Nomenclature:: 0 (Organoplatinum Compounds)
0 (Oxaloacetates)
04ZR38536J (Oxaliplatin)
1406-16-2 (Vitamin D)
6804DJ8Z9U (Capecitabine)
Q573I9DVLP (Leucovorin)
U3P01618RT (Fluorouracil)
SCR Protocol:: Folfox protocol; XELOX
Entry Date(s):: Date Created: 20200125 Date Completed: 20201022 Latest Revision: 20210429
Update Code:: 20240104
DOI:: 10.1007/s00520-020-05319-x
PMID:: 31974772
: Czasopismo naukowe

Full Text Finder

Purpose: We aimed to identify potential clinical parameters that can be easily obtained by a pre-treatment clinicopathological evaluation and whole blood test to estimate the development of oxaliplatin-induced peripheral neuropathy (OIPN).
Methods: This study was conducted retrospectively. For the FOLFOX regimen, patients received oxaliplatin, 85 mg/m 2 , every 2 weeks for 12 courses, and with the XELOX regimen, oxaliplatin was 130 mg/m 2 , every 3 weeks for 6-8 courses. The incidence and degree of neuropathy (NCI-CTCAE v.3) were recorded.
Results: A total of 186 patients were included in the study. There were 108 (58%) patients in the grade 0-1 (G0-G1) neuropathy group (mean age 50.5 ± 11.5; 63% men), and 78 (42%) patients in the grade 2-3 (G2-G3) neuropathy group (mean age 58.0 ± 10.8; 46.2% men). The relationship between G2-G3 OIPN development and age (p < 0.001), gender (p = 0.02), and ECOG performance status (p = 0.007) was statistically significant. In the G2-G3 neuropathy group, serum gamma-glutamyl transferase (GGT) (p < 0.001) and glucose (p = 0.007) levels were higher, whereas vitamin D (p < 0.001), hemoglobin (Hgb) (p < 0.001), serum albumin (p = 0.001), and serum magnesium (p = 0.035) levels were lower compared with the G0-G1 neuropathy group. G2-G3 neuropathy was observed in 88% of patients with mucinous carcinoma pathologic type (p < 0.001).
Conclusion: This study demonstrated that age, histopathologic type, albumin, GGT, glucose, vitamin D, and Hgb levels were the effective factors in prediction of the development of OIPN. In addition, GGT, vitamin D, and Hgb levels were the most effective factor to predict development of OIPN.

Informacja